[go: up one dir, main page]

PE20200404A1 - Composicion farmaceutica de clorhidrato de s-ketamina - Google Patents

Composicion farmaceutica de clorhidrato de s-ketamina

Info

Publication number
PE20200404A1
PE20200404A1 PE2019002098A PE2019002098A PE20200404A1 PE 20200404 A1 PE20200404 A1 PE 20200404A1 PE 2019002098 A PE2019002098 A PE 2019002098A PE 2019002098 A PE2019002098 A PE 2019002098A PE 20200404 A1 PE20200404 A1 PE 20200404A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
ketamine hydrochloride
composition
acid
tudca
Prior art date
Application number
PE2019002098A
Other languages
English (en)
Inventor
Esther D G Basstanie
Johanna Bentz
Roger C A Embrechts
Nico Rudolph Niemeijer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50687638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20200404A1 publication Critical patent/PE20200404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)

Abstract

Se refiere a una composicion farmaceutica acuosa que comprende: un valor equivalente de 125mg/ml a 180mg/ml de clorhidrato de S-Ketamina, un amortiguador seleccionado de acido citrico y de 0.01% a 3% en peso de un componente antioxidante seleccionado de sulfitos, acido ascorbico, entre otros, en donde la composicion tiene un pH de 4,5 a 5,5. Se formula para la administracion nasal y no tiene un conservante antimicrobiano. Dicha composicion comprende ademas 5mg/ml a 10 mg/ml de acido tauroursodesoxicolico (TUDCA).
PE2019002098A 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-ketamina PE20200404A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791237P 2013-03-15 2013-03-15
PCT/US2014/027059 WO2014152196A1 (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride

Publications (1)

Publication Number Publication Date
PE20200404A1 true PE20200404A1 (es) 2020-02-26

Family

ID=50687638

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002098A PE20200404A1 (es) 2013-03-15 2014-03-14 Composicion farmaceutica de clorhidrato de s-ketamina

Country Status (16)

Country Link
US (6) US20140275278A1 (es)
EP (2) EP3636251B1 (es)
KR (1) KR102217616B1 (es)
CN (2) CN111643449A (es)
AU (2) AU2014240102A1 (es)
BR (1) BR112015022972B1 (es)
CL (1) CL2015002736A1 (es)
CR (1) CR20150481A (es)
ES (2) ES2911466T3 (es)
MX (1) MX371392B (es)
MY (1) MY180526A (es)
NI (1) NI201500135A (es)
PE (1) PE20200404A1 (es)
PH (1) PH12015502013B1 (es)
SG (2) SG10201802104QA (es)
WO (1) WO2014152196A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
WO2017003935A1 (en) 2015-06-27 2017-01-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
HUE071303T2 (hu) 2018-09-28 2025-08-28 Novohale Therapeutics Llc Ketamin-készítmény a depresszió tüdõn keresztül való beadással történõ kezelési módszerében való felhasználásra
IL318198A (en) 2019-03-05 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
PL3976145T3 (pl) 2019-05-31 2025-04-28 Celon Pharma S.A. Inhalator do elektronicznie nadzorowanego pozajelitowego podawania kompozycji farmaceutycznej
ES2977185T3 (es) 2019-05-31 2024-08-20 Afyx Dev A/S Administración intranasal de ketamina a pacientes con cefalea en racimos
WO2020239243A1 (en) 2019-05-31 2020-12-03 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
CN114306218B (zh) * 2020-09-30 2023-11-10 四川普锐特药业有限公司 满足药学抑菌要求的经粘膜给药r-氯胺酮药物组合物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
US20250221927A1 (en) * 2022-04-26 2025-07-10 Yichang Humanwell Pharmaceutical Co., Ltd. Esketamine liquid preparation and use thereof
US20250248951A1 (en) * 2022-04-26 2025-08-07 Yichang Humanwell Pharmaceutical Co., Ltd. Esketamine liquid preparation and use thereof
WO2024201274A1 (en) 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Esketamine for use in the treatment of depression
WO2025099181A1 (en) 2023-11-07 2025-05-15 HMNC Holding GmbH Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
AU733284B2 (en) 1995-02-24 2001-05-10 Stuart L. Weg Nasal and ocular administration of ketamine to manage pain and for detoxification
CA2230690C (en) 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
CN1205922C (zh) * 1998-07-24 2005-06-15 柳署弘 制备含有胆汁酸的澄清水溶液剂型
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
WO2002024116A1 (en) 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20040248964A1 (en) 2002-11-18 2004-12-09 Crooks Peter A. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
DK1885414T3 (da) 2005-06-01 2013-02-11 Shl Group Ab Indretning til afgivelse af et lægemiddel
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
EP2012762A4 (en) * 2006-03-22 2010-03-10 Sinai School Medicine INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
JP2009538331A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2009140269A2 (en) * 2008-05-13 2009-11-19 Clarassance, Inc. Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
HUE026619T2 (en) 2010-06-15 2016-06-28 Gruenenthal Gmbh Pharmaceutical combination for the treatment of pain
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
JP6296985B2 (ja) 2011-10-14 2018-03-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用
AU2012340015B2 (en) 2011-11-14 2017-09-21 Alfasigma S.P.A. Assays for selecting a treatment regimen for a subject with depression and methods for treatment
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
MX2014010939A (es) 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2013149102A1 (en) 2012-03-30 2013-10-03 The General Hospital Corporation Compositions comprising scopolamine and ketamine in the treatment of depression
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
AU2013305580A1 (en) 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
AU2014250756B2 (en) 2013-04-12 2019-03-07 Icahn School Of Medicine At Mount Sinai Method for treating post-traumatic stress disorder
EP3960162A1 (en) 2013-08-26 2022-03-02 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
ES2726223T3 (es) 2014-01-14 2019-10-02 Childrens Hospital Med Ct Composiciones que comprenden ketamina para el tratamiento de un trastorno del espectro autista
ES2743699T3 (es) 2014-04-17 2020-02-20 Develco Pharma Schweiz Ag Forma de dosificación oral de ketamina
RU2697382C2 (ru) 2014-05-04 2019-08-13 Фирмениш С.А. Ароматизированные продукты питания и напитки
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017003935A1 (en) 2015-06-27 2017-01-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression

Also Published As

Publication number Publication date
US20190117591A1 (en) 2019-04-25
CN105073096A (zh) 2015-11-18
US20200069612A1 (en) 2020-03-05
AU2019200424A8 (en) 2019-02-21
SG10201802104QA (en) 2018-05-30
CL2015002736A1 (es) 2016-03-28
US11446260B2 (en) 2022-09-20
US20140275278A1 (en) 2014-09-18
US20230241009A1 (en) 2023-08-03
ES2911466T3 (es) 2022-05-19
CR20150481A (es) 2015-10-26
PH12015502013A1 (en) 2016-01-11
BR112015022972A2 (pt) 2017-07-18
KR20150132381A (ko) 2015-11-25
EP3636251A1 (en) 2020-04-15
MX371392B (es) 2020-01-28
BR112015022972B1 (pt) 2023-02-14
EP2968122B1 (en) 2019-08-28
CN111643449A (zh) 2020-09-11
SG11201507347QA (en) 2015-10-29
AU2019200424A1 (en) 2019-02-14
AU2014240102A1 (en) 2015-09-17
NI201500135A (es) 2016-03-16
KR102217616B1 (ko) 2021-02-19
MY180526A (en) 2020-12-01
WO2014152196A1 (en) 2014-09-25
MX2015012617A (es) 2016-06-21
US20140274981A1 (en) 2014-09-18
PH12015502013B1 (en) 2016-01-11
ES2755809T3 (es) 2020-04-23
EP3636251B1 (en) 2022-01-19
EP2968122A1 (en) 2016-01-20
US20250170075A1 (en) 2025-05-29
AU2019200424B2 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
PE20200404A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
PH12014502778B1 (en) Antibody formulation
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
AR098168A1 (es) Formulación estable de insulina glulisina
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
DOP2016000007A (es) Pirazolpiridinas sustituidas
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
BR112014014786A2 (pt) formulações de antibiótico
MX375934B (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
CO2018001531A2 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
PE20210927A1 (es) Composiciones antimicrobianas con agentes efervescentes
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
AR092841A1 (es) Formulaciones de antibiotico
UY34839A (es) Formulaciones de antibiótico
BR112015018930A2 (pt) benzamidas substituídas com atividade para receptores ep4